Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil

NCT03533361 · clinicaltrials.gov ↗
APPROVED_FOR_MARKETING
Status
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Eisai Inc.